This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 2042466 results found since Jan 2013.

Needs and Preferences of Patients With Head-neck Cutaneous SCC
Conditions:   Cutaneous Squamous Cell Carcinoma;   Cutaneous Squamous Cell Carcinoma of the Head and Neck;   Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   Squamous Cell Carcinoma of the Head and Neck;   Skin Cancer;   Patient Satisfaction;   High-Risk Cance r;   Preference, Patient;   Decision Making;   Interview Intervention:   Other: Regular care with additional administration of a semi-structured interview Sponsor:   Maastricht University Medical Center Active, not recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Condition:   Non-Small Cell Lung Cancer Intervention:   Drug: PLB1004 Sponsor:   Avistone Biotechnology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Conditions:   Head Neck;   Squamous Cell Carcinoma of Head and Neck Interventions:   Drug: Pembrolizumab;   Drug: Magrolimab;   Drug: cetuximab;   Drug: Docetaxel Sponsors:   M.D. Anderson Cancer Center;   Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Mantle-Cell;   Lymphoma, Follicular;   Lymphoma, B-Cell Intervention:   Drug: ALETA-001 Sponsors:   Cancer Research UK;   Aleta BioTherapeutics Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Condition:   Advanced Non-small Cell Lung Cancer Intervention:   Drug: almonertinib Sponsor:   Qianfoshan Hospital Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Conditions:   Non-Small Cell Lung Cancer;   NSCLC;   EGFR/HER2 Exon 20 Insertion Mutation Intervention:   Drug: STX-721 Sponsor:   Scorpion Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Condition:   Renal Cell Carcinoma Intervention:   Drug: HS-10516 Sponsor:   Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Conditions:   Metastatic Colorectal Adenocarcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8 Interventions:   Drug: Bendamustine;   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Cyclophosphamide;   Procedure: Echocardiography;   Drug: Fludarabine;   Procedure: Leukapheresis;   Procedure: Magnetic Resonance Imaging;   Procedure: M ultigated Acquisition Scan;   Procedure:...
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition:   Esophageal Squamous Cell Carcinoma Interventions:   Drug: Carrelizumab;   Drug: Paclitaxel injection;   Drug: Cisplatin;   Radiation: Concurrent chemoradiotherapy Sponsor:   The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Condition:   Neoplasms Interventions:   Drug: GSK3901961;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsor:   GlaxoSmithKline Terminated
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Conditions:   Lung Cancer;   TKI Resistance;   EGFR Sensitive Mutation;   Anlotinib;   Pianzumab Interventions:   Drug: Anlotinib;   Drug: Penpulimab Sponsors:   Degan Lu;   Wu Jieping Medical Foundation Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Conditions:   Advanced Solid Tumor;   Refractory Tumor Interventions:   Radiation: Radiotherapy;   Drug: PD-1/PD-L1 inhibitor;   Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection;   Drug: Interleukin 2 subcutaneous injection;   Drug: Endostatin Sponsor:   Second Affiliated Hospital of Soochow University Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions:   NAFLD;   MASLD;   Mild Inflammatory Context Intervention:   Dietary Supplement: TOTUM-448 Sponsors:   Valbiotis;   Clinic'n'Cell;   University Hospital, Clermont-Ferrand Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-cell Lymphoma Intervention:   Biological: RC19D2 cell injection Sponsor:   Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition:   Large B-Cell Lymphoma Interventions:   Drug: Glofitamab;   Drug: Polatuzumab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials